Compare Immunovant Inc. Common Stock (IMVT) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Jumia Technologies AG - ADR — how do they compare? Immunovant Inc. Common Stock trades at $30.3 (market cap $6.25B), while Jumia Technologies AG - ADR trades at $6.48 (market cap $865.90M). The key difference: Immunovant Inc. Common Stock is far larger — about 7.2× Jumia Technologies AG - ADR's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Jumia Technologies AG - ADR for 28 Days on average.
| IMVT | JMIA | |
|---|---|---|
Market Cap | $6.25B | $865.90M |
Volume | 1,755,411 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $14.60 |
52-Week Low | $17.03 | $5.69 |
Typical Hold Time | 0 Days | 28 Days |
Enterprise Value | $5.35B | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JMIA trades at $6.74, down 0.88% with a bearish technical signal despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent $50M capital injection and operational improvements support the path toward EBITDA breakeven by year-end 2026.
Investment outlook balances analyst bullishness (71% buy ratings, $12 consensus target) against persistent profitability challenges. Key opportunities include African e-commerce growth and cost optimization, while risks center on execution timeline and competitive pressures. The stock offers speculative upside if turnaround milestones are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
